FDA OKs Phase 2 Trial of Oral NE3107 in Easing Inflammation

FDA OKs Phase 2 Trial of Oral NE3107 in Easing Inflammation

310592

FDA OKs Phase 2 Trial of Oral NE3107 in Easing Inflammation

The launch of a Phase 2 trial into the safety and early efficacy of oral NE3107 in treating Parkinson’s disease patients with motor fluctuations while on levodopa was approved by the U.S. Food and Drug Administration (FDA), BioVie, the therapy’s developer, announced. BioVie plans to initiate patient enrollment for the trial, called the NM201 study (NCT05083260), before the end of the year, it said in a press release. Results are expected in mid-2022. NE3107 is a small molecule…

You must be logged in to read/download the full post.